Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds
- 1 March 2016
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 174 (3), 621-624
- https://doi.org/10.1111/bjd.14201
Abstract
Vemurafenib is a newly licensed target-directed medication. It has been proven to improve the survival of patients with metastatic melanoma and the BRAF(V600E) mutation; however, adverse cutaneous reactions are frequent. Few cases of life-threatening severe cutaneous adverse reactions (SCARs) induced by vemurafenib have been reported. Dabrafenib, another selective BRAF inhibitor, has been licensed recently as an alternative drug with the same indications. From a molecular point of view, both vemurafenib and dabrafenib contain a sulfonamide group; cross-reactivity to sulfonamide compounds has been reported in allergic patients. We report on a patient with vemurafenib-induced toxic epidermal necrolysis (TEN). In vitro analysis of lymphocyte reactivity to vemurafenib showed positive results, confirming drug causality. In addition, lymphocytes from the patient reacted to dabrafenib and to the antibiotic sulfonamide drug sulfamethoxazole. Moreover, lymphocytes from two patients with cutaneous adverse reactions to sulfamethoxazole also reacted to vemurafenib and dabrafenib in vitro. These data strongly suggest that there might be clinical cross-reactivity between BRAF inhibitors and sulfonamides in some patients. Thus, precautions should be taken to avoid sulfonamide drugs as much as possible in patients showing serious hypersensitivity reactions to vemurafenib and vice versa.Keywords
Funding Information
- Instituto de Salud Carlos III-Ministerio de Economía y Competitividad (FIS PI12/02267, FIS PI13/01768)
This publication has 14 references indexed in Scilit:
- Necrólisis epidérmica tóxica por vemurafenibActas Dermo-Sifiliograficas, 2015
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysisBritish Journal of Dermatology, 2014
- Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanomaBritish Journal of Dermatology, 2014
- Nécrolyse épidermique toxique au vemurafenibAnnales de Dermatologie et de Vénéréologie, 2014
- Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicitiesBritish Journal of Dermatology, 2012
- Successful desensitization in a case of Stevens–Johnson syndrome due to vemurafenibMelanoma Research, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-StudyJournal of Investigative Dermatology, 2008
- The lymphocyte transformation test in the diagnosis of drug hypersensitivityAllergy, 2004